BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15902338)

  • 1. [Results of docetaxel therapy in patients with relapsed ovarian cancer].
    Lehoczky O; Thurzó L; Bagaméri A; Sárosi Z; Udvary J; Pulay T
    Magy Onkol; 2005; 49(1):71-5. PubMed ID: 15902338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [First observations of the dose-dense weekly docetaxel therapy in relapsed ovarian cancer].
    Lehoczky O; Pulay T
    Magy Onkol; 2006; 50(1):43-6. PubMed ID: 16617383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
    Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
    Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer.
    Niwa Y; Nakanishi T; Kuzuya K; Nawa A; Mizutani S
    Int J Clin Oncol; 2003 Dec; 8(6):343-7. PubMed ID: 14663634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel: an alternative taxane in ovarian cancer.
    Katsumata N
    Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
    Kushner DM; Connor JP; Sanchez F; Volk M; Schink JC; Bailey HH; Harris LS; Stewart SL; Fine J; Hartenbach EM;
    Gynecol Oncol; 2007 May; 105(2):358-64. PubMed ID: 17258800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Docetaxel and carboplatin for epithelial ovarian cancer].
    Misawa H; Misawa A; Ueta K; Saitou M; Yasuda M
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):903-6. PubMed ID: 15222109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel in the management of ovarian cancer.
    Blagden SP; Kaye SB
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):203-14. PubMed ID: 15877518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Docetaxel and ovarian cancer].
    Ray-Coquard I
    Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
    Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F
    Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
    Pokrzywinski R; Secord AA; Havrilesky LJ; Puls LE; Holloway RW; Lewandowski GS; Higgins RV; Nycum LR; Kohler MF; Revicki DA
    Gynecol Oncol; 2011 Dec; 123(3):505-10. PubMed ID: 21945310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.
    Secord AA; Blessing JA; Armstrong DK; Rodgers WH; Miner Z; Barnes MN; Lewandowski G; Mannel RS;
    Gynecol Oncol; 2008 Mar; 108(3):493-9. PubMed ID: 18191993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective weekly docetaxel for recurrent ovarian cancer: A case report.
    Komiyama S; Mizusawa Y; Onouchi M; Takehara K; Suzuki A; Mikami M
    Int J Gynecol Cancer; 2003; 13(5):683-6. PubMed ID: 14675355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
    Alvarez Secord A; Berchuck A; Higgins RV; Nycum LR; Kohler MF; Puls LE; Holloway RW; Lewandowski GS; Valea FA; Havrilesky LJ
    Cancer; 2012 Jul; 118(13):3283-93. PubMed ID: 22072307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    J Clin Oncol; 2001 Apr; 19(7):1901-5. PubMed ID: 11283121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
    Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
    Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
    Pfisterer J; du Bois A; Wagner U; Quaas J; Blohmer JU; Wallwiener D; Hilpert F;
    Gynecol Oncol; 2004 Mar; 92(3):949-56. PubMed ID: 14984965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.